Although a belimumab surrogate (i.e., anti-mouse BAFF mAb) has not yet been evaluated in the experimental MG models, treatment of EAMG mice with low doses of a BAFF-R-specific mAb-siRNA conjugate, designed to mediate depletion of BAFF-R+ B cells, was associated with EAMG amelioration without affecting autoAb levels (54). The gene discussed is TNFRSF13C; the disease is myasthenia gravis.